Item 2.02. Results of Operations and Financial Condition
On January 5, 2023, Astria Therapeutics, Inc. (the "Company") is making publicly
available on its website a corporate presentation (the "Corporate
Presentation"). A copy of the Corporate Presentation is furnished herewith as
Exhibit 99.1 to this Current Report on Form 8-K.
As disclosed in the Corporate Presentation, although it has not finalized its
full financial results for the fourth quarter and fiscal year ended December 31,
2022, on a preliminary and unaudited basis, the Company had approximately $226
million of cash, cash equivalents and short-term investments as of December 31,
2022 (the "Financial Information"), which, based on the Company's current
operating plan is estimated to enable the Company to fund its operating expenses
and capital expenditure requirements through the first half of 2025.
The Financial Information contained in this Item 2.02 of this Current Report on
Form 8-K is unaudited and preliminary, subject to the completion of the
Company's financial closing procedures, and does not present all information
necessary for an understanding of the Company's financial condition as of
December 31, 2022, and its results of operations for the three months and year
ended December 31, 2022. The audit of the Company's consolidated financial
statements for the year ended December 31, 2022, is ongoing and could result in
changes to the Financial Information. In addition, the Company has based its
estimate regarding its cash runway on assumptions that may prove to be wrong,
and the Company could use its available capital resources sooner than it
currently expects.
The information in this Item 2.02 of this Current Report on Form 8-K, including
the Corporate Presentation, is being furnished and shall not be deemed "filed"
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the "Exchange Act"), or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act,
except as expressly set forth by specific reference in such a filing.
Item 7.01. Regulation FD Disclosure
On January 5, 2023, the Company is making publicly available on its website the
Corporate Presentation. A copy of the Corporate Presentation is furnished
herewith as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 7.01 of this Current Report on Form 8-K, including
the Corporate Presentation, is being furnished and shall not be deemed "filed"
for purposes of Section 18 of the Exchange Act or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act or the Exchange Act, except as expressly set
forth by specific reference in such a filing.
Item 8.01. Other Events
As disclosed in the Corporate Presentation, there were 27,501,340 shares of the
Company's common stock issued and outstanding as of December 30, 2022,
reflecting the issuance of shares of common stock pursuant to the previously
announced underwritten offering in December 2022, including the exercise of the
option granted by the Company to the underwriters to purchase additional shares
of common stock.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
99.1 Copy of the Company's corporate presentation (furnished herewith)
Cover Page Interactive Data File (embedded within the Inline XBRL
104 document)
Forward Looking Statements
Any statements in this Current Report on Form 8-K about future expectations,
plans and prospects for the Company, including statements about the Company's
estimated cash, cash equivalents and short-term investments as of December 31,
2022, and anticipated cash runway, among other things, constitute
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. The words "aims," "anticipate," "believe,"
"estimate," "expect," "may," "could," and other words and terms of similar
meaning are intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. You should not place
undue reliance on these statements. Actual results may differ materially from
those indicated by such forward-looking statements as a result of various
important factors, including: risks and uncertainties inherent in the initiation
and completion of preclinical studies and clinical trials and clinical
development of the Company's product candidates; whether interim results from a
clinical trial will be predictive of the final results of the trial or the
results of future trials; expectations for regulatory approvals to conduct
trials or to market products; potential changes in estimated cash, cash
equivalents and marketable securities based on the completion of financial
closing procedures and release of complete fiscal 2022 results; availability of
funding sufficient for the Company's foreseeable and unforeseeable operating
expenses and capital expenditure requirements; other matters that could affect
the availability or commercial potential of the Company's product candidates;
and other factors discussed in the "Risk Factors" section of the Company's
Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed
with the U.S. Securities and Exchange Commission ("SEC"), and in other filings
that the Company may make with the SEC in the future. In addition, the
forward-looking statements included in this Current Report on Form 8-K represent
the Company's views as of the date hereof and should not be relied upon as
representing the Company's views as of any date subsequent to the date hereof.
The Company anticipates that subsequent events and developments will cause the
Company's views to change. However, while the Company may elect to update these
forward-looking statements at some point in the future, the Company specifically
disclaims any obligation to do so.
© Edgar Online, source Glimpses